


D-dimer/high-sensitivity troponin I ratio in the diagnosis of acute pulmonary embolism and/or non-ST-elevation myocardial infarction

Aysun Sahin, MD^a, Akkan Avci, MD^b, Hayri Cinar, MD^b, Erdem Aksay, MD^b, Yeliz Simsek, MD^{b,*} , Senem Derya Tatar, MD^c, Mustafa Yilmaz Gok, MD^c, Ozge Yildirim, MD^c, Abdullah Yildirim, MD^d, Sadiye Yolcu, MD^c, Onder Yesiloglu, MD^e, Ozlem Ercen Diken, MD^f, Begum Seyda Avci, MD^g

Abstract

This study aimed to determine whether the D-dimer/high-sensitivity troponin I (hs-TnI) ratio is useful in the differential diagnosis of acute pulmonary embolism (APE) and/or non-ST-elevation myocardial infarction (NSTEMI) in patients who presented to the emergency department with chest pain. The study included 219 patients with APE and 385 patients with NSTEMI over the age of 18 who presented to the emergency department with chest pain and were diagnosed with either APE or NSTEMI. Using statistical analysis, D-dimer, hs-TnI, creatine kinase myocardial band (CK-MB) levels, D-dimer/CK-MB, and D-dimer/hs-TnI ratios were compared in patients with APE and NSTEMI. The D-dimer/hs-TnI ratio in patients with APE was found to be considerably greater than in patients with NSTEMI. Similarly, the D-dimer/CK-MB levels in patients with APE were significantly higher than in individuals with NSTEMI. Patients with APE had higher D-dimer levels, while those with NSTEMI had higher hs-TnI levels. The D-dimer/hs-TnI ratio can be useful for emergency clinicians because it is affordable, quickly calculated, and easily accessible.

Abbreviations: ACS = acute coronary syndrome, APE = acute pulmonary embolism, AUC = area under the curve, CK-MB = creatine kinase myocardial band, DBP = diastolic blood pressure, ED = emergency department, hs-TnI = high-sensitivity troponin I, MAP = mean arterial blood pressure, NSTEMI = non-ST-elevation myocardial infarction, ROC = receiver operating characteristic, SaO₂ = Saturation percentage, SBP = systolic blood pressure.

Keywords: acute pulmonary embolism, D-dimer, high-sensitivity troponin I, non-ST-elevation myocardial infarction

1. Introduction

Two commonly encountered clinical symptoms in the emergency room are shortness of breath and sudden chest discomfort.^[1] Because of the high risk of mortality and morbidity in acute coronary syndrome (ACS) and acute pulmonary embolism (APE), both should both be diagnosed promptly in these patients and adequate follow-up should be provided after establishing a differential diagnosis. Therefore, selecting the correct therapeutic approach in a timely manner is crucial in these situations.

Medical history, physical examination, and cardiac risk factors might not be enough to differentiate between similar conditions that present with chest pain.^[2] One of the biomarkers used to exclude the diagnosis of APE is the D-dimer protein

fragment. Although normal or low levels of D-dimer is useful for excluding venous thromboembolic events, high levels have low specificity and sensitivity for confirming pulmonary embolism diagnosis.^[3] This low specificity is because several other thrombotic diseases, including ACS, increase serum D-dimer levels, which is a fibrin breakdown product.^[4,5] Given the pathophysiology of APE, right ventricular load contributes to increased serum levels of high-sensitivity troponin I (hs-TnI), just as in ACS.

The D-dimer/hs-TnI ratio is easy to use and can be more effective than using each biomarker alone. Studies in the literature show that the ratio is a suitable parameter to use in the differential diagnosis of chest pain, such as APE, ACS, or thoracic acute aortic syndrome.^[6-8]

The authors have no funding and conflicts of interest to disclose.

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

The ethics committee of the Adana City Training and Research Hospital approved the study.

This article has not been presented anywhere.

^a Emergency Medicine Clinic, Reyhanli State Hospital, Hatay, Turkey, ^b Emergency Department, Adana City Research and Training Hospital, Health Science University, Adana, Turkey, ^c Department of Emergency, Health Science University, Adana City Research and Training Hospital, Adana, Turkey, ^d Department of Cardiology, Health Science University, Adana City Research and Training Hospital, Adana, Turkey, ^e Department of Emergency Medicine, Health Science University, Adana City Research and Training Hospital, Adana, Turkey, ^f Department of Thoracic Diseases, Health Science University, Adana City Research and Training Hospital, Adana, Turkey, ^g Department of Internal Medicine, Adana City Research and Training Hospital, Health Science University, Adana, Turkey.

* Correspondence: Yeliz Simsek, Emergency Department, Adana City Research and Training Hospital, Health Science University, 38000 Adana, Turkey (e-mail: ylzberk@yahoo.com).

Copyright © 2025 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and build upon the work provided it is properly cited. The work cannot be used commercially without permission from the journal.

How to cite this article: Sahin A, Avci A, Cinar H, Aksay E, Simsek Y, Tatar SD, Gok MY, Yildirim O, Yildirim A, Yolcu S, Yesiloglu O, Diken OE, Avci BS. D-dimer/high-sensitivity troponin I ratio in the diagnosis of acute pulmonary embolism and/or non-ST-elevation myocardial infarction. *Medicine* 2025;104:20(e41975).

Received: 21 November 2024 / Received in final form: 7 March 2025 / Accepted: 10 March 2025

<http://dx.doi.org/10.1097/MD.00000000000041975>

This study aimed to investigate whether the D-dimer/hs-TnI ratio is effective in the differential diagnosis of APE and non-ST-elevation myocardial infarction (NSTEMI). We also wanted to establish whether this practical ratio could be helpful for the differential diagnosis of these 2 important diseases in the emergency department (ED) setting.

2. Materials and methods

This retrospective, cross-sectional case study conducted at a single institution. The study began following approval and conducted in accordance with the Helsinki declaration.

2.1. Participant selection

Patients who presented to the ED with a complaint of chest pain and were diagnosed with APE and/or NSTEMI between January 1, 2020 and January 1, 2022 were included in the study. The APE diagnosis was based on file records and/or computed tomography pulmonary angiogram, whereas NSTEMI diagnosis was based on hs-TnI levels. The pediatric age group (age <18 years), patients whose records could not be completely accessed, and patients with diagnoses other than APE and NSTEMI due to chest pain were all excluded from the study.

2.2. Study methods

During the data collection phase of the study, the vital signs (i.e., mean of pulse rate, systolic blood pressure [SBP], diastolic blood pressure [DBP], mean arterial blood pressure [MAP], fever, and oxygen saturation percentage), laboratory results at

the time of admission, electrocardiography results, time spent in the ED, hospitalization time, and discharge details were also documented in addition to the patients' demographic details. Deaths that occurred during hospitalization were also recorded.

Blood samples to measure biochemical and complete blood count parameters were taken. The complete blood count results included hemoglobin, hematocrit, and platelets readings. The following biochemical parameters were also evaluated: glucose, albumin, sodium, potassium, calcium, urea, creatinine, alanine transaminase, hs-TnI, creatine kinase myocardial band (CK-MB), and D-dimer levels.

2.3. Statistical analysis

All data were calculated and analyzed using SPSS v25.0 software. Data were expressed as mean \pm standard deviation for continuous variables and percentages for categorical variables. The Kolmogorov-Smirnov test was used to determine the normality of continuous variables. Normally distributed variables were reported as mean \pm standard deviation, while nonnormally distributed parameters were expressed as median with interquartile range (IQR_{25–75}). The Student *t* test and Mann-Whitney *U* were used to compare continuous data. The Chi-squared test was used to compare categorical variables. Variables determined to be significant in univariate studies were used in the multivariate logistic regression analysis. The receiver operating characteristic (ROC) curve analysis was used to evaluate the predictive power of 4 inflammatory indices: hs-TnI, CK-MB, D-dimer, D-dimer/CK-MB ratio, and D-dimer/hs-TnI ratio. The area under the curve (AUC; <0.50 indicating no discrimination and >0.80 indicating good discrimination) was calculated for each index to measure diagnostic accuracy along with 95% confidence interval for precision. ROC curves were plotted to illustrate the sensitivity and specificity, offering a clear comparison of their performance. The optimal cutoff value was established using the maximum Youden index. Statistical comparisons of AUCs were conducted using the DeLong method to ensure robust evaluation of diagnostic accuracy. All statistical analyses used 2-sided tests with a significance level (α) of 0.05.

3. Results

Six hundred four patients were included of which 219 were patients diagnosed with APE and 385 with NSTEMI. The mean age of patients with APE (66.4 \pm 14.8 years) was statistically higher than patients with NSTEMI (61.8 \pm 12.0 years; *P* < .001). Of the patients with APE, 53% (*n* = 116) were female and 47% (*n* = 103) were male. Of the patients with NSTEMI, 64.9% (*n* = 250) were male, compared to 35.1% (*n* = 135) who

Table 1
The patients' vital signs and laboratory findings at the moment of admission to the emergency department.

Variables	APE (n = 219)	NSTEMI (n = 385)	P-value*
Age (yr)	66.4 \pm 14.8	61.8 \pm 12.0	<.001
Female gender, n (%)	116 (53.0)	135 (35.1)	<.001
Temperature (°C)	36.6 \pm 0.5	36.5 \pm 0.3	.078
Pulse (beat/min)	106 \pm 19	90 \pm 14	<.001
SBP (mm Hg)	118 \pm 27	133 \pm 25	<.001
DBP (mm Hg)	75 \pm 15	82 \pm 13	<.001
MAP (mm Hg)	89 \pm 17	100 \pm 17	<.001
SaO ₂ (%)	90 \pm 8	96 \pm 5.5	<.001
Laboratory parameters	Mean \pm SD	Mean \pm SD	
Glucose (mg/dL)	172 \pm 85	136 \pm 83	<.001
Urea (mg/dL)	51 \pm 30	40 \pm 21	<.001
Creatinine (mg/dL)	1.0 \pm 0.5	0.9 \pm 0.5	.049
Sodium (mmol/L)	137 \pm 5	136 \pm 4	.079
Potassium (mEq/L)	4.4 \pm 0.6	4.3 \pm 0.5	.077
Calcium (mg/L)	9.0 \pm 2.4	9.4 \pm 2.7	.149
ALT	26 \pm 14.8	24 \pm 12	.239
White blood cell	13.3 \pm 4.8	11.9 \pm 4.1	.083
Hemoglobin (g/dL)	12.1 \pm 2.1	13.2 \pm 1.8	<.001
Hematocrit (%)	36.8 \pm 6.9	39.5 \pm 5.4	<.001
Platelet ($\times 10^3$ /uL)	246 \pm 105	255 \pm 72	.218
Albumin (g/L)	34.0 \pm 5.7	37.6 \pm 3.9	<.001

ALT = alanine transaminase, APE = acute pulmonary embolism, DBP = diastolic blood pressure, dL = deciliter, g = gram, L = liter, MAP = mean arterial blood pressure, mEq = milliequivalent, mg = milligram, min = minute, mm Hg = millimeters of mercury, mmol = millimoles, NSTEMI = non-ST-elevation myocardial infarction, SaO₂ (%) = oxygen saturation percentage, SBP = systolic blood pressure, SD = standard deviation, U = unit.

* A *P*-value of <.05 was considered statistically significant. As appropriate, *P*-value was calculated using an independent samples *t* test or the Mann-Whitney *U*-test for continuous variables and a Chi-squared test or the Fishers exact test for categorical variables.

Table 2
Cardiac evaluation and mortality rates.

Variables	APE (n = 219)	NSTEMI (n = 385)	P-value*
Ejection fraction, (%)	50 \pm 10	48 \pm 11	.178
hs-TnI (pg/mL)	32 (12–153)	2099 (845–5250)	<.001
CK-MB (mcg/L)	2.4 (1.4–3.9)	16.5 (5.0–55.9)	<.001
D-dimer (mcg/L)	7620 (3810–15,390)	520 (260–1250)	<.001
D-dimer/hs-TnI ratio	214 (58–642)	0.28 (0.10–0.85)	<.001
D-dimer/ CK-MB ratio	3130 (1375–6115)	34 (10–110)	<.001

Values are presented as numbers (*n*) and percentages (%) or median (interquartile range).

P-value was calculated using the Mann-Whitney *U*-test for continuous variables and the Chi-squared test or the Fishers exact test for categorical variables, as appropriate.

APE = acute pulmonary embolism, CK-MB = creatine kinase-myocardial band, hs-TnI = high-sensitivity troponin I, mcg/L = microgram/liter, NSTEMI = non-ST-elevation myocardial infarction, pg/mL = picogram/milliliter.

* A *P*-value of <.05 was considered statistically significant.

were female. Compared to those with NSTEMI, the female sex ratio in patients diagnosed with APE was significantly higher ($P < .001$).

Patient vital signs at ED admission are summarized in Table 1. There were statistically significant differences in the mean pulse rate, SBP, DBP, MAP, and oxygen saturation between the APE and the NSTEMI patient groups ($P < .001$); however, no significant statistical difference in the temperature measured. Laboratory values obtained at the time of ED admission are given in Table 1. Hemoglobin, hematocrit, urea, and albumin values were statistically significantly different between both groups (all $P < .001$).

Patient cardiac evaluations and mortality rates are summarized in Table 2 and Figure 1. The ejection fractions of the 2 patient groups did not differ significantly. The hs-TnI, CK-MB, D-dimer level, and D-dimer/CK-MB and D-dimer/hs-TnI ratios were statistically significantly different between both groups (all $P < .001$). After admission to the hospital, patients with APE had an in-hospital mortality rate of 21.1% ($n = 46$), whereas patients with NSTEMI had a rate of 2.9% ($n = 11$). The difference in mortality rates was significantly higher in patients with APE ($P < .001$).

The ROC analysis comparison of the performances of hs-TnI, D-dimer, CK-MB, D-dimer/CK-MB, and D-dimer/hs-TnI parameters in discriminating APE from NSTEMI are shown in Table 3 and Figure 2. According to the ROC analysis, all 5 variables were statistically significant and are shown in Table 4 (all $P < .001$). The ratio of D-dimer/hs-TnI (>4.4) had 99.5% sensitivity and 94.0% specificity (AUC 0.995) among the predictive values determined by the AUC, which suggests that this ratio is the most significant factor for differentiating APE from NSTEMI.

4. Discussion

Literature research reveals some reports of the usefulness of using the D-dimer/Troponin I ratio ratio to distinguish

between APE and NSTEMI, both of which cause chest pain.^[6] No studies have investigated the use D-dimer/hs-TnI ratio in this context. In our study, we found that D-dimer/hs-TnI (>4.4) had higher sensitivity and specificity than hs-TnI and D-dimer alone in differentiating APE from NSTEMI. The main conclusion of our study was that D-dimer/hs-TnI ratio could be useful as an independent and effective parameter to distinguish between APE and NSTEMI in patients presenting to the ED with chest pain.

Chest pain is one of the commonest complaints of patients presenting to the ED.^[10] In patients presenting with chest pain, APE and ACS are 2 life-threatening conditions that should be identified or ruled promptly. Large-scale multicenter studies have shown that compared to traditional tests, hs-TnI tests improve the diagnostic accuracy for identifying NSTEMI and allow quicker diagnosis and exclusion of ACS, particularly in patients who present to the ED immediately following the onset of chest pain.^[11] Another critical diagnosis among patients with chest discomfort is APE. Clinical findings, electrocardiography, laboratory parameters, and chest radiology are used in the diagnosis of APE.^[12–14] The primary biomarker that is used to rule out the diagnosis of APE is D-dimer, which is a fibrin breakdown product formed following fibrin production and destruction.^[15–18] The emergency medicine physicians frequently use plasma D-dimer levels to differentiate between ACS and APE.^[19,20] Thrombus in the coronary arteries of patients with NSTEMI can result in increased D-dimer levels.^[15] Given the pathophysiological mechanisms involved, it is well known that pulmonary embolism (PE) might also result in increased cardiac marker levels and right ventricular involvement.^[3,21] Elevated cardiac troponin in PE is related to the prognosis and severity of the disease rather than the diagnosis.^[22,23] According to some studies, patients with massive PE had greater cardiac troponin levels than patients without.^[24,25] In our study, we observed that patients with APE had lower hs-TnI levels than those with NSTEMI.

In a study conducted by Kim et al, patients with APE had a significantly higher D-dimer/Troponin-I ratio (50.6 ± 85.3




Figure 1. Analysis of hs-TnI, D-dimer, D-dimer/hs-TnI, D-dimer/CK-MB values in pulmonary embolism and NSTEMI patients. CK-MB = creatine kinase myocardial band, hs-TnI = high-sensitivity troponin I, NSTEMI = non-ST-elevation myocardial infarction.

vs 1.6 ± 5.7 , $P < .001$) than those with NSTEMI. An D-dimer/Troponin-I ratio >1.82 has been reported to have higher sensitivity and specificity for discriminating APE with increased troponin from acute NSTEMI.^[6] However hs-TnI was not the cardiac biomarker used in this study. Among cardiac troponins, hs-TnI has the highest sensitivity and specificity for the diagnosis of NSTEMI, hence why hs-TnI was used as the primary cardiac biomarker in our study.

Our study showed that the D-dimer/CK-MB ratio could be a useable marker for the differential diagnosis of APE and NSTEMI. We were unable to find any studies that looked into this ratio in our literature review. Nevertheless, the study by He et al showed that CK-MB alone can be used for the differential diagnosis of NSTEMI and APE.^[26]

In our study, the female sex ratio was higher in the APE group, whereas the male sex ratio was higher in the NSTEMI group ($P < .001$), which is corroborated in the literature.^[6,8]

Our research showed that patients with APE had significantly higher in-hospital mortality rates than those with NSTEMI. For patients with APE, hemodynamic stability is vital. According to a study, patients with APE had a higher 30-day mortality rate when their SBP levels decreased.^[27] According to a large population-based study conducted in patients with acute myocardial infarction, low SBP is an independent and strong predictor of 1-year cardiovascular mortality.^[28] Hemodynamic instability and high D-dimer levels in patients with APE are associated with the severity of APE. In our research, patients with APE had much lower SBP and DBP (including MAP, which is related to these 2 blood pressures),

Table 3

ROC analysis comparing performance of D-dimer, hs-TnI, CK-MB, D-dimer/CK-MB, and D-dimer/hs-TnI parameters in identifying non-ST-elevation myocardial infarction from pulmonary embolism.

Variable	AUC	Cutoff value†	Sensitivity (%)	Specificity (%)	SE	95% CI‡	P-value*
hs-TnI	0.942	≤ 544	93.2	80.3	0.010	0.92–0.96	$< .001$
CK-MB	0.855	≤ 4.4	79.9	77.5	0.002	0.82–0.88	$< .001$
D-dimer	0.952	> 1565	94.5	83.6	0.009	0.94–0.97	$< .001$
D-dimer/hs-TnI ratio	0.995	> 4.4	99.5	94.0	0.002	0.99–0.99	$< .001$
D-dimer/CK-MB ratio	0.980	> 428.6	95.4	92.1	0.005	0.97–0.99	$< .001$

AUC = area under the curve, CI = confidence interval, CK-MB = creatine kinase myocardial band, hs-TnI = high-sensitivity troponin I, SE = standard error.

† Calculated a maximal Youden index.

‡ Binomial exact.

* A P-value of $< .05$ was considered statistically significant.




Figure 2. ROC analysis comparing performance of D-dimer, hs-TnI, D-dimer/CK-MB, and D-dimer/hs-TnI parameters in identifying NSTEMI from pulmonary embolism. CK-MB = creatine kinase myocardial band, hs-TnI = high-sensitivity troponin I, NSTEMI = non-ST-elevation myocardial infarction, ROC = receiver operating characteristic.

Table 4

Receiver operating characteristic curve analysis comparing performance of D-dimer, hs-TnI, D-dimer/CK-MB, and D-dimer/hs-TnI parameters in identifying non-ST-elevation myocardial infarction from pulmonary embolism.

Variables	Difference between AUC [†]	95% CI	P-value*
hs-TnI–D-dimer	0.0126	–0.02 to 0.04	0.363
hs-TnI–D-dimer/hs-TnI ratio	0.0553	0.04–0.07	<.001
hs-TnI–D-dimer/CK-MB ratio	0.0406	0.02–0.06	<.001
D-dimer–D-dimer/hs-TnI ratio	0.0427	0.03–0.06	<.001
D-dimer–D-dimer/CK-MB ratio	0.0281	0.01–0.04	<.001
D-dimer/hs-TnI ratio–D-dimer/CK-MB ratio	0.0146	0.01–0.02	<.001

AUC = area under the curve, CI = confidence interval, CK-MB = creatine kinase myocardial band, hs-TnI = high-sensitivity troponin I.

[†] DeLong et al^[9].

* A P < .05 was considered statistically significant.

than those with NSTEMI. In addition to these findings, hemoglobin, hematocrit, urea, albumin, and glucose abnormalities were statistically significant in the APE group. These results might explain the significantly higher mortality rate in the APE group.^[29–31] Early interventional revascularization could be the reason for less cardiac damage and lower mortality in patients with NSTEMI.

5. Limitations

This was a single-center, retrospective study. There was bias in the patient selection due to the nature of the retrospective design and the number of patients was relatively small. There was also a difference between the time onset of patients' symptoms and the time of blood tests. We could not obtain information about the patients' comorbidities and the medications they used. Since computed tomography pulmonary angiogram was not performed on all patients, APE that might have accompanied patients with NSTEMI could not be recognized.

6. Conclusion

Our research showed that the D-dimer/hs-TnI ratio is a useful and independent indicator in the differential diagnosis of APE and NSTEMI in patients who present to the ED with chest pain. We believe that emergency medicine physicians will benefit from this parameter because it is cheap, easily available, and quick to determine. Clearer results regarding the D-dimer/hs-TnI ratio's dependability can be obtained from large series, multicenter studies, and randomized controlled trials. Our work could serve as a foundation for further research.

Author contributions

Conceptualization: Aysun Sahin, Akkan Avci, Hayri Cinar, Erdem Aksay, Yeliz Simsek, Senem Derya Tatar, Mustafa Yilmaz Gok, Ozge Yildirim, Abdullah Yildirim, Sadiye Yolcu, Onder Yesiloglu, Ozlem Ercen Diken, Begum Seyda Avci.

Data curation: Aysun Sahin, Akkan Avci, Hayri Cinar, Erdem Aksay, Senem Derya Tatar, Mustafa Yilmaz Gok, Ozge Yildirim, Abdullah Yildirim, Sadiye Yolcu, Onder Yesiloglu, Ozlem Ercen Diken, Begum Seyda Avci.

Formal analysis: Aysun Sahin, Akkan Avci, Hayri Cinar, Erdem Aksay, Yeliz Simsek, Senem Derya Tatar, Mustafa Yilmaz Gok, Ozge Yildirim, Abdullah Yildirim, Sadiye Yolcu, Onder Yesiloglu, Ozlem Ercen Diken, Begum Seyda Avci.

Investigation: Aysun Sahin, Hayri Cinar, Erdem Aksay, Mustafa Yilmaz Gok, Ozge Yildirim, Abdullah Yildirim, Sadiye Yolcu, Onder Yesiloglu, Ozlem Ercen Diken, Begum Seyda Avci.

Methodology: Aysun Sahin, Akkan Avci, Hayri Cinar, Erdem Aksay, Yeliz Simsek, Senem Derya Tatar, Mustafa Yilmaz Gok, Ozge Yildirim, Abdullah Yildirim, Sadiye Yolcu, Onder Yesiloglu, Ozlem Ercen Diken, Begum Seyda Avci.

Software: Aysun Sahin.

Supervision: Aysun Sahin, Akkan Avci, Hayri Cinar, Ozlem Ercen Diken.

Validation: Aysun Sahin, Akkan Avci, Hayri Cinar, Erdem Aksay, Mustafa Yilmaz Gok, Ozge Yildirim, Abdullah Yildirim, Sadiye Yolcu, Onder Yesiloglu, Ozlem Ercen Diken, Begum Seyda Avci.

Visualization: Aysun Sahin, Akkan Avci, Hayri Cinar, Erdem Aksay, Senem Derya Tatar, Mustafa Yilmaz Gok, Ozge Yildirim, Abdullah Yildirim, Sadiye Yolcu, Onder Yesiloglu, Ozlem Ercen Diken, Begum Seyda Avci.

Writing – original draft: Aysun Sahin, Akkan Avci, Hayri Cinar, Erdem Aksay, Yeliz Simsek, Senem Derya Tatar, Mustafa Yilmaz Gok, Ozge Yildirim, Abdullah Yildirim, Sadiye Yolcu, Onder Yesiloglu, Ozlem Ercen Diken, Begum Seyda Avci.

Writing – review & editing: Aysun Sahin, Akkan Avci, Hayri Cinar, Erdem Aksay, Yeliz Simsek, Senem Derya Tatar, Mustafa Yilmaz Gok, Ozge Yildirim, Abdullah Yildirim, Sadiye Yolcu, Onder Yesiloglu, Ozlem Ercen Diken, Begum Seyda Avci.

References

- [1] Duru S, Keleşoğlu A, Ardiç S. Clinical update on pulmonary embolism. *Arch Med Sci.* 2014;10:557–65.
- [2] Chang AM, Fischman DL, Hollander JE. Evaluation of chest pain and acute coronary syndromes. *Cardiol Clin.* 2018;36:1–12.
- [3] Wells PS, Owen C, Doucette S, Fergusson D, Tran H. Does this patient have deep vein thrombosis? *JAMA.* 2006;295:199–207.
- [4] Bayes-Genis A, Mateo J, Santaló M, et al. D-Dimer is an early diagnostic marker of coronary ischemia in patients with chest pain. *Am Heart J.* 2000;140:379–84.
- [5] Sakamoto K, Yamamoto Y, Okamatsu H, Okabe M. D-dimer is helpful for differentiating acute aortic dissection and acute pulmonary embolism from acute myocardial infarction. *Hellenic J Cardiol.* 2011;52:123–7.
- [6] Kim JY, Kim KH, Cho JY, et al. D-dimer/troponin ratio in the differential diagnosis of acute pulmonary embolism from non-ST elevation myocardial infarction. *Korean J Intern Med.* 2019;34:1263–71.
- [7] Lee M, Kim YW, Lee D, et al. The D-dimer to troponin ratio is a novel marker for the differential diagnosis of thoracic acute aortic syndrome from non-ST elevation myocardial infarction. *J Clin Med.* 2023;12:3054.
- [8] Urfalioglu AB, Altug E, Cinar H, et al. D-dimer/high sensitive troponin I ratio is useful in predicting in-hospital mortality in pulmonary embolism patients. *Ir J Med Sci.* 2024;193:2695–703.
- [9] DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. *Biometrics.* 1988;44:837–45.
- [10] Beiser DG, Cifu AS, Paul J. Evaluation and diagnosis of chest pain. *JAMA.* 2022;328:292–3.
- [11] Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation [published correction appears in *Eur Heart J.* 2021;42:1289–367].
- [12] Kozaci N, Ay MO, Beydilli I, et al. Right-sided electrocardiogram usage in acute pulmonary embolism. *Am J Emerg Med.* 2016;34:1437–41.
- [13] Kaptein FHJ, Kroft LJM, Hammerschlag G, et al. Pulmonary infarction in acute pulmonary embolism. *Thromb Res.* 2021;202:162–9.
- [14] Palm V, Rengier F, Rajiah P, Heussel CP, Partovi S. Acute pulmonary embolism: imaging techniques, findings, endovascular treatment and differential diagnoses. *Rofo.* 2020;192:38–49.
- [15] Adam SS, Key NS, Greenberg CS. D-dimer antigen: current concepts and future prospects. *Blood.* 2009;113:2878–87.
- [16] Ariens RA, de Lange M, Snieder H, Boothby M, Spector TD, Grant PJ. Activation markers of coagulation and fibrinolysis in twins: heritability of the prethrombotic state. *Lancet.* 2002;359:667–71.
- [17] Rosendaal FR. Venous thrombosis: a multicausal disease. *Lancet.* 1999;353:1167–73.
- [18] Favresse J, Lippi G, Roy PM, et al. D-dimer: Preanalytical, analytical, postanalytical variables, and clinical applications. *Crit Rev Clin Lab Sci.* 2018;55:548–77.

- [19] Crawford F, Andras A, Welch K, Sheares K, Keeling D, Chappell FM. D-dimer test for excluding the diagnosis of pulmonary embolism. *Cochrane Database Syst Rev*. 2016;2016:CD010864.
- [20] Mussa FF, Horton JD, Moridzadeh R, Nicholson J, Trimarchi S, Eagle KA. Acute aortic dissection and intramural hematoma: a systematic review. *JAMA*. 2016;316:754–63.
- [21] Wells PS, Anderson DR, Rodger M, et al. Excluding pulmonary embolism at the bedside without diagnostic imaging: management of patients with suspected pulmonary embolism presenting to the emergency department by using a simple clinical model and d-dimer. *Ann Intern Med*. 2001;135:98–107.
- [22] Janata K, Holzer M, Laggner AN, Müllner M. Cardiac troponin T in the severity assessment of patients with pulmonary embolism: cohort study. *BMJ*. 2003;326:312–3.
- [23] Becattini C, Vedovati MC, Agnelli G. Prognostic value of troponins in acute pulmonary embolism: a meta-analysis. *Circulation*. 2007;116:427–33.
- [24] Amorim S, Dias P, Rodrigues RA, et al. Troponin I as a marker of right ventricular dysfunction and severity of pulmonary embolism. *Rev Port Cardiol*. 2006;25:181–6.
- [25] Kucher N, Goldhaber SZ. Cardiac biomarkers for risk stratification of patients with acute pulmonary embolism. *Circulation*. 2003;108:2191–4.
- [26] He Z, Bi W, Lang Z, et al. Comparative study on electrocardiograms and serological examinations of acute pulmonary embolism and acute non-ST elevation myocardial infarction. *Ann Noninvasive Electrocardiol*. 2021;27:e12920.
- [27] Quezada A, Jiménez D, Bikkdeli B, et al. Systolic blood pressure and mortality in acute symptomatic pulmonary embolism. *Int J Cardiol*. 2020;302:157–63.
- [28] Mouhat B, Putot A, Hanon O, et al; Observatoire des Infarctus de Côte d'Or Survey. Low systolic blood pressure and mortality in elderly patients after acute myocardial infarction. *J Am Heart Assoc*. 2020;9:e013030.
- [29] Cheng S, Shen H, Han Y, Han S, Lu Y. Association between stress hyperglycemia ratio index and all-cause mortality in critically ill patients with atrial fibrillation: a retrospective study using the MIMIC-IV database. *Cardiovasc Diabetol*. 2024;23:363.
- [30] Jäntti T, Tarvasmäki T, Harjola VP, et al; CardShock investigators. Hypoalbuminemia is a frequent marker of increased mortality in cardiogenic shock. *PLoS One*. 2019;14:e0217006.
- [31] Lawler PR, Filion KB, Dourian T, Atallah R, Garfinkle M, Eisenberg MJ. Anemia and mortality in acute coronary syndromes: a systematic review and meta-analysis. *Am Heart J*. 2013;165:143–53.e5.